AzurRx BioPharma registers $15 million stock for initial public sale

WallachBeth Capital, Network 1 Financial Securities are bookrunners

By Devika Patel

Knoxville, Tenn., July 13 – AzurRx BioPharma, Inc. will price its initial public offering of common stock with a 30-day greenshoe, according to a Form S-1 filed Wednesday with the Securities and Exchange Commission. The company has registered up to $15 million of stock for the deal.

WallachBeth Capital, LLC and Network 1 Financial Securities, Inc. are the bookrunners.

Proceeds will be used for clinical development, preclinical programs, working capital and other general corporate purposes.

The gastrointestinal research company is based in Brooklyn, N.Y. The company intends to list its common stock on the Nasdaq under the symbol “AZRX.”

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.